Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy-Reference-Cited by-同舟云学术

Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy

Published:2014-05-27 Issue:4 Volume:3 Page:980-987
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Fernanda Amary M.¹²,Ye Hongtao¹,Berisha Fitim¹,Khatri Bhavisha¹,Forbes Georgina¹,Lehovsky Katie¹,Frezza Anna M.²³,Behjati Sam⁴,Tarpey Patrick⁴,Pillay Nischalan¹²,Campbell Peter J.⁴,Tirabosco Roberto¹,Presneau Nadège²,Strauss Sandra J.²³,Flanagan Adrienne M.¹²

Affiliation:

1. Histopathology; London Sarcoma Service; Royal National Orthopaedic Hospital NHS Trust; Stanmore Middlesex HA7 4LP U.K

2. UCL Cancer Institute; Huntley Street London WC1E 6BT U.K

3. University College London Hospitals Foundation Trust; London Sarcoma Service; 250 Euston Road London NW1 2PG U.K

4. Cancer Genome Project; Wellcome Trust Sanger Institute; Wellcome Trust Genome Campus Hinxton Cambridgeshire CB10 1SA U.K

Funder

National Institute for Health Research, University College London Hospitals Biomedical Research Centre

Skeletal Cancer Action Trust (SCAT)

UCL Experimental Cancer Centre

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Reference29 articles.

1. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity;Link;N. Engl. J. Med.,1986

2. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors;Sandberg;Cancer Genet. Cytogenet.,2003

3. Frequency of mouse double minute 2 (MDM2) and mouse double minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes;Duhamel;Histopathology,2012

4. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup;Hauben;Eur. J. Cancer,2002

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating druggable kinases for targeted therapy in retinoblastoma;Journal of Human Genetics;2024-07-01

2. Amicis Omnia Sunt Communia: NF-κB Inhibition as an Alternative to Overcome Osteosarcoma Heterogeneity;Pharmaceuticals;2024-06-05

3. Osteosarcomas With Few Chromosomal Alterations or Adult Onset Are Genetically Heterogeneous;Laboratory Investigation;2024-01

4. Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa;Journal of Bone Oncology;2023-12

5. FGFR families: biological functions and therapeutic interventions in tumors;MedComm;2023-09-23